Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 192.14B | 198.20B | 175.39B | 161.29B | 136.74B |
Gross Profit | 51.60B | 50.80B | 57.38B | 55.65B | 50.59B |
EBITDA | 329.02M | 30.50B | 477.14M | 4.05B | 5.02B |
Net Income | -4.35B | 1.38B | 538.72M | 10.08B | 8.00B |
Balance Sheet | |||||
Total Assets | 796.53B | 808.39B | 823.15B | 806.28B | 767.72B |
Cash, Cash Equivalents and Short-Term Investments | 152.32B | 152.65B | 157.80B | 164.77B | 173.54B |
Total Debt | 241.86B | 233.57B | 228.36B | 257.87B | 250.87B |
Total Liabilities | 598.99B | 599.81B | 623.52B | 603.16B | 574.64B |
Stockholders Equity | 118.10B | 124.94B | 121.52B | 131.00B | 127.81B |
Cash Flow | |||||
Free Cash Flow | 15.61B | -3.35B | -5.45B | -9.64B | 2.73B |
Operating Cash Flow | 26.88B | 9.82B | 1.76B | -3.32B | 8.89B |
Investing Cash Flow | -126.97M | 17.59B | 35.58B | -536.96M | 612.52M |
Financing Cash Flow | -14.27B | -39.67B | -38.12B | -3.66B | 2.29B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
81 Outperform | £154.64B | 10.41 | 10.86% | 3.33% | -3.40% | -7.51% | |
58 Neutral | HK$10.50B | 4.22 | -2.96% | 7.40% | 3.76% | -51.26% | |
52 Neutral | HK$38.45B | 44.05 | -3.59% | 0.42% | -4.89% | -404.51% | |
$20.69B | 17.14 | 11.92% | 2.92% | ― | ― | ||
$28.34B | 12.53 | 11.23% | 4.44% | ― | ― | ||
$34.29B | 14.50 | 2.88% | 4.38% | ― | ― | ||
€96.97B | 5.79 | 19.25% | 7.24% | ― | ― |
Fosun International, through its subsidiary Henlius, has announced the proposed adoption of a Share Option Scheme and an RSU Scheme, which are subject to shareholder approval. These schemes aim to grant options and RSUs to participants, potentially reducing Fosun’s shareholding in Henlius from 63.43% to 58.73%, constituting a discloseable transaction under the Hong Kong Listing Rules.
Fosun International Limited has announced the grant of 49,530,000 share options to 154 directors and employees as part of its 2023 Option Scheme. This move aims to incentivize and retain key management and staff, potentially enhancing the company’s performance and competitiveness in its diverse sectors.
Fosun International Limited has appointed Mr. Luo Yuanli as a non-executive director, effective June 16, 2025. Mr. Luo, currently with Zhongrong Life Insurance, brings experience in management and compliance, and his appointment is expected to enhance the board’s diversity. This strategic move reflects Fosun’s commitment to strengthening its leadership team and potentially improving its governance and operational oversight.
Fosun International Limited has announced the composition of its board of directors, which includes executive, non-executive, and independent non-executive directors. The announcement also details the roles and functions of each director within various board committees, highlighting the company’s governance structure.
Fosun International’s subsidiary, Yuyuan, is facilitating a capital increase for its Jewelry Fashion Group, aiming to raise up to RMB2 billion from no more than 40 investors. This strategic move involves a series of transactions that will result in a deemed disposal of equity interest, reducing Fosun’s indirect holding in the group to 91.03%. The transaction is classified as a major one under Hong Kong’s Listing Rules, necessitating shareholder approval and adherence to reporting requirements.
Fosun International Limited has outlined the terms of reference for its Nomination Committee, which is tasked with reviewing the board’s structure, size, and diversity, as well as recommending changes to align with the company’s corporate strategy. This move is aimed at enhancing governance and ensuring the board’s composition supports the company’s strategic goals, potentially impacting its operational efficiency and stakeholder confidence.
Fosun International Limited held its Annual General Meeting on June 5, 2025, where all proposed resolutions were passed with significant support. Key resolutions included the approval of financial statements, the declaration of a final dividend, the re-election of directors, and the authorization for share repurchase and issuance mandates. These decisions reflect the company’s strategic focus on maintaining strong governance and enhancing shareholder value.
Fosun International Limited has announced a supplemental agreement to the Sale and Purchase Agreement concerning the disposal of equity interest in Guangzhou Taotall Technology Co., Ltd. to Hangzhou Tianyuan Pet Products Co., Ltd. The supplemental agreement amends the terms of the original agreement, with the appraised value of Guangzhou Taotall set at RMB777 million. The transaction is contingent upon approvals from the shareholders and boards of both companies, as well as regulatory bodies.
Fosun International has announced a discloseable transaction involving its subsidiaries, Fidelidade – Property Europe, S.A., and others, entering into a Promissory Sale and Purchase Agreement with Banco de Portugal. This agreement involves the sale of future units, including basement carparks, of buildings A2 and A3 of the Entrecampos Project in Lisbon, Portugal, for a base consideration of EUR191,990,000. The transaction is significant as it exceeds 5% of applicable percentage ratios, making it a discloseable transaction under the Listing Rules, and highlights Fosun International’s strategic move in the real estate market.
Fosun High Technology reported a slight decrease in total assets by 0.4% and a marginal increase in equity attributable to owners by 0.3% for the first quarter of 2025. However, the company experienced a significant decline in revenue from operations by 32.9% and a drop in profit attributable to owners by 27.3% compared to the same period last year, indicating challenges in maintaining its financial performance.
Fosun International’s subsidiary, Shanghai Yuyuan Tourist Mart, reported a significant decline in its financial performance for the first quarter of 2025, with a 49% drop in revenue and a 71.24% decrease in net profit compared to the same period last year. This downturn reflects challenges in the market, potentially impacting stakeholders’ confidence and the company’s industry positioning.
Fosun International Limited has announced a discloseable transaction concerning the acquisition of unlisted shares of Henlius. This acquisition involves multiple shareholders, with Ms. Tseng Chi-Ling being the largest shareholder of HenLink, the seller. This strategic move is expected to enhance Fosun’s market positioning and potentially impact its stakeholders by expanding its investment portfolio.
Fosun International Limited has announced its upcoming Annual General Meeting (AGM) scheduled for June 5, 2025, in Shanghai, China. Key agenda items include the presentation of audited financial statements for 2024, the declaration of a final dividend, re-election of directors, and the reappointment of Ernst & Young as auditors. Additionally, resolutions will be considered for the authorization of share purchases and the issuance of new shares, which could impact the company’s market positioning and shareholder value.
Fosun International, through its subsidiary Fosun Pharma Industrial, has increased its stake in Henlius by acquiring additional shares, bringing its total ownership to 63.43%. This acquisition, conducted through a series of transactions, highlights Fosun’s strategic focus on expanding its influence in the pharmaceutical sector. The transactions are classified as discloseable under Hong Kong’s Listing Rules, indicating their significance to the company’s financial and operational strategies.
Fosun International Limited announced the resignation of Mr. Yu Qingfei from his position as a non-executive director, effective April 11, 2025, due to a reallocation of work. The company expressed gratitude for Mr. Yu’s contributions, and he confirmed no disagreements with the board, ensuring no issues for shareholders or the Hong Kong Stock Exchange.